Increased levels of YKL-40 and interleukin 6 in patients with chronic pancreatitis and secondary diabetes

Pancreas

Volumn 41, Issue 8, 2012, Pages 1316-1318

  Hansen, Morten ^a   Nielsen, Anders Rinnov ^a,b   Vilsbøll, Tina ^a   Lund, Asger ^a   Krarup, Thure ^c   Knop, Filip Krag ^a   Vestergaard, Henrik ^d  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Rigshospitalet   (Denmark)

^c BISPEBJERG HOSPITAL   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

chronic pancreatitis; interleukin 6 (IL 6); secondary diabetes; YKL 40

Indexed keywords

INTERLEUKIN 6; PROTEIN; UNCLASSIFIED DRUG; YKL 40 PROTEIN;

ADULT; AGED; ARTICLE; CHRONIC PANCREATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; GLUCOSE TOLERANCE; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADIPOKINES; ADULT; AGED; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; INTERLEUKIN-6; LECTINS; MALE; MIDDLE AGED; PANCREATITIS, CHRONIC;

EID: 84868303489     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31824d9b93     Document Type: Article

References (21)

1. Johansen JS, Williamson MK, Rice JS, et al. Identification of proteins secreted by human osteoblastic cells in culture. J Bone Miner Res. 1992;7:501-512.
2. Rehli M, Krause SW, Andreesen R. Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics. 1997;43:221-225.
3. Shackelton LM, Mann DM, Millis AJ. Identification of a 38-kDa heparin-binding glycoprotein (gp38k) in differentiating vascular smooth muscle cells as a member of a group of proteins associated with tissue remodeling. J Biol Chem. 1995;270:13076-13083.
4. Hakala BE, White C, Recklies AD. Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J Biol Chem. 1993;268:25803-25810.
5. Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull. 2006;53:172-209.
6. Recklies AD, White C, Ling H. The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways. Biochem J. 2002;365:119-126.
7. Ling H, Recklies AD. The chitinase 3-like protein human cartilage glycoprotein 39 inhibits cellular responses to the inflammatory cytokines interleukin-1 and tumour necrosis factor-alpha. Biochem J. 2004;380:651-659.
8. Johansen JS, Jensen BV, Roslind A, et al. Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev. 2006;15:194-202.
9. Rathcke CN, Vestergaard H. YKL-40, a new inflammatory marker with relation to insulin resistance and with a role in endothelial dysfunction and atherosclerosis. Inflamm Res. 2006;55:221-227.
10. DeFronzo RA, Gunnarsson R, Bjorkman O, et al. Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus. J Clin Invest. 1985;76:149-155.
11. Shin SJ, Lee YJ, Hsaio PJ, et al. Relationships between beta-cell function and diabetic duration and albuminuria in type 2 diabetes mellitus. Pancreas. 1997;14:192-198.
12. Rathcke CN, Johansen JS, Vestergaard H. YKL-40, a biomarker of inflammation, is elevated in patients with type 2 diabetes and is related to insulin resistance. Inflamm Res. 2006;55:53-59.
13. Nielsen AR, Erikstrup C, Johansen JS, et al. Plasma YKL-40: a BMI-independent marker of type 2 diabetes. Diabetes. 2008;57:3078-3082.
14. Cardellini M, Andreozzi F, Laratta E, et al. Plasma interleukin-6 levels are increased in subjects with impaired glucose tolerance but not in those with impaired fasting glucose in a cohort of Italian Caucasians. Diabetes Metab Res Rev. 2007;23:141-145.
15. Nielsen AR, Plomgaard P, Krabbe KS, et al. IL-6, but not TNF-alpha, increases plasma YKL-40 in human subjects. Cytokine. 2011;55:152-155.
16. Knop FK, Vilsboll T, Hojberg PV, et al. Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? Diabetes. 2007;56:1951-1959.
17. Layer P, Yamamoto H, Kalthoff L, et al. The different courses of early- and late-onset idiopathic and alcoholic chronic pancreatitis. Gastroenterology. 1994;107:1481-1487.
18. Harvey S, Weisman M, O'Dell J, et al. Chondrex: new marker of joint disease. Clin Chem. 1998;44:509-516.
19. Bojesen SE, Johansen JS, Nordestgaard BG. Plasma YKL-40 levels in healthy subjects from the general population. Clin Chim Acta. 2011;412:709-712.
20. Krabbe KS, Pedersen M, Bruunsgaard H. Inflammatory mediators in the elderly. Exp Gerontol. 2004;39:687-699.
21. Talar-Wojnarowska R, Gasiorowska A, Smolarz B, et al. Clinical significance of interleukin-6 (IL-6) gene polymorphism and IL-6 serum level in pancreatic adenocarcinoma and chronic pancreatitis. Dig Dis Sci. 2009;54:683-689.